Clinical trial
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
NCT00496873 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00496873 |
|---|---|
| Title | Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan |
| Official title | A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan ("PCR") in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Astex Pharmaceuticals, Inc. Industry Pharmatech |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Cytoxan, Nipent, Rituxan |
| Enrollment | 100 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Jul 4, 2007 |
| Last update posted | Mar 29, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: